Larimar Therapeutics Inc (LRMR) Stock AnalysisLRMRLarimar Therapeutics Inc

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Larimar Therapeutics Inc (LRMR) is currently trading at $2.67, which is significantly below the analyst price targets, indicating potential upside. However, the RSI is at a very low 11.77, suggesting the stock is oversold, but the company has reported substantial net losses, including a net loss of $32.8 million in Q2 2026. The main risk is the company's ongoing negative earnings trend, with an EPS of -0.30 reported last quarter, which could deter investors.